Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Chimerix

Nasdaq:CMRX
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CMRX
Nasdaq
$92M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. The last earnings update was 32 days ago. More info.


Add to Portfolio Compare Print
  • Chimerix has significant price volatility in the past 3 months.
CMRX Share Price and Events
7 Day Returns
15.5%
NasdaqGM:CMRX
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-29%
NasdaqGM:CMRX
1.6%
US Biotechs
-9.1%
US Market
CMRX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Chimerix (CMRX) 15.5% -13.9% -27% -29% -76.6% -96%
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • CMRX underperformed the Biotechs industry which returned 1.6% over the past year.
  • CMRX underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
CMRX
Industry
5yr Volatility vs Market

Value

 Is Chimerix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Chimerix. This is due to cash flow or dividend data being unavailable. The share price is $1.49.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Chimerix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Chimerix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:CMRX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.03
NasdaqGM:CMRX Share Price ** NasdaqGM (2020-03-27) in USD $1.49
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Chimerix.

NasdaqGM:CMRX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CMRX Share Price ÷ EPS (both in USD)

= 1.49 ÷ -2.03

-0.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Chimerix is loss making, we can't compare its value to the US Biotechs industry average.
  • Chimerix is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Chimerix's expected growth come at a high price?
Raw Data
NasdaqGM:CMRX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
17.2%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Chimerix, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Chimerix's assets?
Raw Data
NasdaqGM:CMRX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.79
NasdaqGM:CMRX Share Price * NasdaqGM (2020-03-27) in USD $1.49
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:CMRX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CMRX Share Price ÷ Book Value per Share (both in USD)

= 1.49 ÷ 1.79

0.83x

* Primary Listing of Chimerix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Chimerix is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Chimerix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Chimerix has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Chimerix expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Chimerix expected to grow at an attractive rate?
  • Unable to compare Chimerix's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Chimerix's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Chimerix's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:CMRX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:CMRX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 17.2%
NasdaqGM:CMRX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 15.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:CMRX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:CMRX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 20 -59 1
2023-12-31 20 -53 1
2022-12-31 35 -28 -41 2
2021-12-31 35 -31 -37 2
2020-12-31 7 -42 -54 2
2020-03-28
NasdaqGM:CMRX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 13 -75 -113
2019-09-30 11 -80 -124
2019-06-30 9 -51 -66
2019-03-31 9 -51 -67
2018-12-31 7 -54 -69
2018-09-30 4 -58 -74
2018-06-30 5 -56 -75
2018-03-31 4 -55 -73
2017-12-31 4 -50 -71
2017-09-30 5 -48 -67
2017-06-30 4 -49 -66
2017-03-31 6 -49 -68

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Chimerix is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Chimerix's revenue is expected to grow by 15.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:CMRX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Chimerix Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CMRX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.65 -0.65 -0.65 1.00
2023-12-31 -0.65 -0.65 -0.65 1.00
2022-12-31 -0.58 -0.55 -0.60 2.00
2021-12-31 -0.56 -0.55 -0.57 2.00
2020-12-31 -0.87 -0.79 -0.95 2.00
2020-03-28
NasdaqGM:CMRX Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.03
2019-09-30 -2.35
2019-06-30 -1.32
2019-03-31 -1.36
2018-12-31 -1.43
2018-09-30 -1.54
2018-06-30 -1.58
2018-03-31 -1.55
2017-12-31 -1.51
2017-09-30 -1.43
2017-06-30 -1.43
2017-03-31 -1.46

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Chimerix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Chimerix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Chimerix has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Chimerix performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Chimerix's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Chimerix does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Chimerix's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Chimerix's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Chimerix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Chimerix Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CMRX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 12.52 -112.58 19.26
2019-09-30 10.62 -124.03 21.12
2019-06-30 9.03 -66.38 24.19
2019-03-31 8.78 -67.34 21.83
2018-12-31 7.22 -69.47 23.58
2018-09-30 4.20 -73.76 26.19
2018-06-30 4.72 -74.99 27.66
2018-03-31 4.21 -73.06 27.29
2017-12-31 4.49 -70.98 27.15
2017-09-30 4.63 -66.70 25.18
2017-06-30 4.39 -66.42 24.36
2017-03-31 5.55 -67.88 24.68
2016-12-31 5.70 -76.39 25.01
2016-09-30 6.83 -99.28 28.84
2016-06-30 8.45 -114.70 31.53
2016-03-31 10.75 -121.37 32.10
2015-12-31 10.76 -117.37 31.30
2015-09-30 8.81 -99.78 26.93
2015-06-30 7.72 -84.28 24.73
2015-03-31 4.50 -71.20 20.38
2014-12-31 4.04 -59.31 17.53
2014-09-30 3.76 -47.24 13.83
2014-06-30 3.49 -36.99 9.54
2014-03-31 3.38 -46.30 8.90
2013-12-31 4.37 -70.55 8.33
2013-09-30 7.07 -68.36 7.19
2013-06-30 27.02 -55.69 7.00
2013-03-31 32.41 -35.60 6.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Chimerix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Chimerix has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Chimerix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Chimerix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Chimerix has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Chimerix's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Chimerix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Chimerix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Chimerix's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Chimerix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -1.0636871815901E+18x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Chimerix Company Filings, last reported 2 months ago.

NasdaqGM:CMRX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 109.95 0.00 113.48
2019-09-30 111.95 0.00 116.72
2019-06-30 149.12 0.00 158.40
2019-03-31 164.31 0.00 171.59
2018-12-31 177.60 0.00 186.53
2018-09-30 189.14 0.00 183.36
2018-06-30 191.39 0.00 174.76
2018-03-31 205.69 0.00 160.45
2017-12-31 221.81 0.00 151.52
2017-09-30 236.90 0.00 149.72
2017-06-30 249.66 0.00 148.53
2017-03-31 263.37 0.00 161.70
2016-12-31 276.22 0.00 232.02
2016-09-30 287.35 0.00 249.67
2016-06-30 299.97 0.00 272.82
2016-03-31 313.70 0.00 263.34
2015-12-31 335.46 0.00 220.33
2015-09-30 370.21 0.38 220.80
2015-06-30 399.31 1.48 258.33
2015-03-31 257.52 2.89 174.50
2014-12-31 274.64 4.30 234.58
2014-09-30 176.61 5.70 188.42
2014-06-30 190.68 7.09 200.60
2014-03-31 89.62 8.48 99.92
2013-12-31 98.54 9.87 109.98
2013-09-30 105.13 11.31 116.90
2013-06-30 111.04 12.70 123.03
2013-03-31 7.57 14.00 22.92
  • Chimerix's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (1.6% vs 0% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Chimerix has sufficient cash runway for 1.5 years based on current free cash flow.
  • Chimerix has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 3.7% each year.
X
Financial health checks
We assess Chimerix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Chimerix has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Chimerix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Chimerix dividends.
If you bought $2,000 of Chimerix shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Chimerix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Chimerix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:CMRX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:CMRX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Chimerix has not reported any payouts.
  • Unable to verify if Chimerix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Chimerix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Chimerix has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Chimerix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Chimerix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Chimerix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Chimerix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Sherman
AGE 53
TENURE AS CEO 0.9 years
CEO Bio

Mr. Michael A. Sherman, also known as Mike, has been Chief Executive Officer of Chimerix, Inc. since April 8, 2019 and serves as President and Director since April 2019. Mr. Sherman served as the Chief Executive Officer and President of Endocyte, Inc. since June 20, 2016. Mr. Sherman served as the Chief Financial Officer of Endocyte, Inc. since October 11, 2006 until February 2017 and its Chief Operating Officer since June 16, 2014 until June 20, 2016. He served as the Principal Accounting Officer of Endocyte, Inc., until May 26, 2011. Mr. Sherman served as a Director of Finance at Guidant Sales Corporation from March 1997 to March 2000. While at Guidant, he served several senior management positions, including Vice President for Finance and IT, Europe, Middle East, Africa and Canada and Corporate Controller and Chief Accounting Officer. He served as a Director for Corporate Financial Planning from 1994 to March 1997. He served positions in audit, domestic and international financial planning and reporting, business development and treasury while with Lilly and served as VP Finance and Strategic Planning at Guidant LLC from May 2004 to October 2006. He was a Director of Endocyte, Inc. since June 20, 2016 until December 21, 2018. He served as a Director of Mead Johnson Nutrition Company from February 26, 2015 to June 15, 2017. Mr. Sherman serves on the Indianapolis Children’s Museum Board of Trustees. He received his Masters in Business Administration from The Amos Tuck School at Dartmouth University and Graduated as a Tuck Scholar. Mr. Sherman holds a B.A. in Economics from DePauw University.

CEO Compensation
  • Insufficient data for Mike to compare compensation growth.
  • Insufficient data for Mike to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Chimerix management team in years:

3.2
Average Tenure
49
Average Age
  • The tenure for the Chimerix management team is about average.
Management Team

William Nichols

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
50
TENURE
5.5 yrs

Mike Sherman

TITLE
CEO, President & Director
AGE
53
TENURE
0.9 yrs

Mike Andriole

TITLE
Chief Business Officer & CFO
AGE
46
TENURE
0.8 yrs

David Jakeman

TITLE
Executive Director of Finance & Accounting and Principal Accounting Officer
AGE
42
TENURE
0.8 yrs

Roy Ware

TITLE
Chief Manufacturing & Technology Officer
TENURE
3.2 yrs

Randall Lanier

TITLE
Chief Science Officer
TENURE
3.2 yrs

Michelle LaSpaluto

TITLE
Vice President of Strategic Planning & Investor Relations
TENURE
4.2 yrs

Michael Alrutz

TITLE
Senior VP
AGE
49
TENURE
5.5 yrs
Board of Directors Tenure

Average tenure and age of the Chimerix board of directors in years:

2
Average Tenure
67
Average Age
  • The average tenure for the Chimerix board of directors is less than 3 years, this suggests a new board.
Board of Directors

Martha Demski

TITLE
Chairman of the Board
COMPENSATION
$135K
AGE
66
TENURE
1.8 yrs

Mike Sherman

TITLE
CEO, President & Director
AGE
53
TENURE
0.9 yrs

Fred Middleton

TITLE
Independent Director
COMPENSATION
$272K
AGE
70
TENURE
2 yrs

Edward Greissing

TITLE
Independent Director
COMPENSATION
$267K
AGE
68
TENURE
2 yrs

Robert Meyer

TITLE
Independent Director
COMPENSATION
$266K
AGE
60
TENURE
2 yrs

Seth Rudnick

TITLE
Member of Scientific Advisory Board
AGE
70

Douglas Richman

TITLE
Member of Scientific Advisory Board

Earl Kern

TITLE
Member of Scientific Advisory Board

Michael Boeckh

TITLE
Member of Clinical Advisory Board

Raymund Razonable

TITLE
Member of Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Chimerix individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
17. Mar 20 Buy Michael Andriole Individual 16. Mar 20 16. Mar 20 33,300 $1.43 $47,522
16. Mar 20 Buy Fred Middleton Individual 12. Mar 20 12. Mar 20 50,000 $1.40 $69,900
16. Mar 20 Buy Michael Sherman Individual 12. Mar 20 12. Mar 20 72,995 $1.45 $105,653
11. Feb 20 Sell William Nichols Individual 07. Feb 20 10. Feb 20 -11,355 $1.70 $-19,165
11. Feb 20 Sell David Jakeman Individual 07. Feb 20 07. Feb 20 -2,290 $1.70 $-3,893
08. Jan 20 Sell William Nichols Individual 07. Jan 20 07. Jan 20 -30,680 $2.15 $-66,045
13. Nov 19 Buy Fred Middleton Individual 11. Nov 19 13. Nov 19 50,000 $1.82 $87,757
07. Nov 19 Buy Michael Andriole Individual 06. Nov 19 06. Nov 19 100,000 $1.56 $156,000
06. Nov 19 Buy Robert Meyer Individual 06. Nov 19 06. Nov 19 10,000 $1.58 $15,797
29. May 19 Buy Martha Demski Individual 28. May 19 28. May 19 18,000 $3.60 $64,800
20. May 19 Buy Michael Sherman Individual 20. May 19 20. May 19 30,000 $3.48 $104,316
13. May 19 Buy Fred Middleton Individual 10. May 19 10. May 19 30,000 $2.92 $87,678
X
Management checks
We assess Chimerix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Chimerix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Could The Chimerix, Inc. (NASDAQ:CMRX) Ownership Structure Tell Us Something Useful?

Taking a look at our data on the ownership groups (below), it's seems that institutional investors have bought into the company. … Insider Ownership Of Chimerix The definition of company insiders can be subjective, and does vary between jurisdictions. … But other times, private equity is selling out, having taking the company public.

Simply Wall St -

Those Who Purchased Chimerix (NASDAQ:CMRX) Shares Five Years Ago Have A 85% Loss To Show For It

View our latest analysis for Chimerix Chimerix isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … Over five years, Chimerix grew its revenue at 2.5% per year. … It is all well and good that insiders have been buying shares, but we suggest you check here to see what price insiders were buying at.

Simply Wall St -

Introducing Chimerix (NASDAQ:CMRX), The Stock That Tanked 85%

Check out our latest analysis for Chimerix Given that Chimerix didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … In the last half decade, Chimerix saw its revenue increase by 2.5% per year. … We'd recommend focussing any further research on the likelihood of profitability in the foreseeable future, given the muted revenue growth.

Simply Wall St -

Should You Take Comfort From Insider Transactions At Chimerix, Inc. (NASDAQ:CMRX)?

For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.' Check out our latest analysis for Chimerix The Last 12 Months Of Insider Transactions At Chimerix CEO, President & Director Michael Sherman made the biggest insider purchase in the last 12 months. … NasdaqGM:CMRX Recent Insider Trading, May 31st 2019 Chimerix is not the only stock insiders are buying. … While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that Chimerix insiders are reasonably well aligned, and optimistic for the future.

Simply Wall St -

How Do Analysts See Chimerix, Inc. (NASDAQ:CMRX) Performing In The Next Couple Of Years?

(NASDAQ:CMRX) announced its latest earnings update, which … company earnings became less negative compared to the previous year's level … - great news for investors

Simply Wall St -

What Kind Of Shareholder Appears On The Chimerix, Inc.'s (NASDAQ:CMRX) Shareholder Register?

The big shareholder groups in Chimerix, Inc. … Chimerix is not a large company by global standards. … institutions own shares in the company.

Simply Wall St -

Some Chimerix Shareholders Have Taken A Painful 93% Share Price Drop

Chimerix isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … When a company doesn't make profits, we'd generally expect to see good revenue growth. … As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Simply Wall St -

Does The Chimerix, Inc. (NASDAQ:CMRX) Share Price Tend To Follow The Market?

(NASDAQ:CMRX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

How Many Chimerix, Inc. (NASDAQ:CMRX) Shares Do Institutions Own?

Generally speaking, as a company grows, institutions will increase their ownership. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Are Insiders Selling Chimerix Inc (NASDAQ:CMRX) Stock?

So shareholders might well want to know whether insiders have been buying or selling shares in Chimerix Inc (NASDAQ:CMRX). … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … The Last 12 Months Of Insider Transactions At Chimerix.

Simply Wall St -

Company Info

Description

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of several key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize DSTAT; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Details
Name: Chimerix, Inc.
CMRX
Exchange: NasdaqGM
Founded: 2000
$91,993,562
61,740,646
Website: http://www.chimerix.com
Address: Chimerix, Inc.
2505 Meridian Parkway,
Suite 100,
Durham,
North Carolina, 27713,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CMRX Common Stock Nasdaq Global Market US USD 11. Apr 2013
DB CXF Common Stock Deutsche Boerse AG DE EUR 11. Apr 2013
BRSE CXF Common Stock Berne Stock Exchange CH CHF 11. Apr 2013
Number of employees
Current staff
Staff numbers
43
Chimerix employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:15
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/02/26
Last earnings filing: 2020/02/25
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.